Intra-Cellular Therapies to Host Third Quarter 2020 Financial Results Conference Call and Webcast
November 04, 2020 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer
October 01, 2020 16:30 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
September 15, 2020 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Present at the Cantor Virtual Global Healthcare Conference
September 14, 2020 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Prices Public Offering of Common Stock
September 10, 2020 20:30 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company, today announced the pricing of its previously announced underwritten public...
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
September 09, 2020 16:01 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company, today announced that it has commenced an underwritten public offering of $350...
Intra-Cellular Therapies Announces Positive Topline Results from Study 402 Evaluating Lumateperone as Adjunctive Therapy in Patients with Bipolar Depression
September 09, 2020 07:00 ET
|
Intra-Cellular Therapies Inc.
Lumateperone 42 mg achieved statistically significant results in primary and key secondary endpoints in Study 402. Company expects to submit supplemental new drug application (sNDA) to the U.S. Food...
Intra-Cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 10, 2020 07:30 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Host Second Quarter 2020 Financial Results Conference Call and Webcast
August 04, 2020 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces Positive Top-line Results from ITI-214 Phase I/II Study in Patients with Heart Failure
June 29, 2020 08:00 ET
|
Intra-Cellular Therapies Inc.
Study demonstrated inhibiting phosphodiesterase-1 with ITI-214 in patients with heart failure improved cardiac function by enhancing cardiac contractility and dilating systemic arteries without...